177 related articles for article (PubMed ID: 19118043)
1. Reoxygenation of hypoxic glioblastoma multiforme cells potentiates the killing effect of an interleukin-13-based cytotoxin.
Liu TF; Cai J; Gibo DM; Debinski W
Clin Cancer Res; 2009 Jan; 15(1):160-8. PubMed ID: 19118043
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme.
Han J; Puri RK
J Neurooncol; 2018 Feb; 136(3):463-474. PubMed ID: 29168083
[TBL] [Abstract][Full Text] [Related]
3. Evidence that IL-13R alpha2 chain in human glioma cells is responsible for the antitumor activity mediated by receptor-directed cytotoxin therapy.
Kawakami K; Kioi M; Liu Q; Kawakami M; Puri RK
J Immunother; 2005; 28(3):193-202. PubMed ID: 15838375
[TBL] [Abstract][Full Text] [Related]
4. Molecular targeting with recombinant cytotoxins of interleukin-13 receptor alpha2-expressing glioma.
Mintz A; Gibo DM; Madhankumar AB; Debinski W
J Neurooncol; 2003; 64(1-2):117-23. PubMed ID: 12952292
[TBL] [Abstract][Full Text] [Related]
5. Analysis of target genes induced by IL-13 cytotoxin in human glioblastoma cells.
Han J; Yang L; Puri RK
J Neurooncol; 2005 Mar; 72(1):35-46. PubMed ID: 15803373
[TBL] [Abstract][Full Text] [Related]
6. Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme: implications for targeted therapies.
Jarboe JS; Johnson KR; Choi Y; Lonser RR; Park JK
Cancer Res; 2007 Sep; 67(17):7983-6. PubMed ID: 17804706
[TBL] [Abstract][Full Text] [Related]
7. Decreasing expression of the interleukin-13 receptor IL-13Ralpha2 in treated recurrent malignant gliomas.
Bozinov O; Kalk JM; Krayenbühl N; Woernle CM; Sure U; Bertalanffy H
Neurol Med Chir (Tokyo); 2010; 50(8):617-21. PubMed ID: 20805641
[TBL] [Abstract][Full Text] [Related]
8. Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy.
Kioi M; Husain SR; Croteau D; Kunwar S; Puri RK
Technol Cancer Res Treat; 2006 Jun; 5(3):239-50. PubMed ID: 16700620
[TBL] [Abstract][Full Text] [Related]
9. Anti-glioblastoma effect of a recombinant bispecific cytotoxin cotargeting human IL-13 and EGF receptors in a mouse xenograft model.
Stish BJ; Oh S; Vallera DA
J Neurooncol; 2008 Mar; 87(1):51-61. PubMed ID: 18084721
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside.
Husain SR; Puri RK
J Neurooncol; 2003 Oct; 65(1):37-48. PubMed ID: 14649884
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy.
Kioi M; Kawakami M; Shimamura T; Husain SR; Puri RK
Cancer; 2006 Sep; 107(6):1407-18. PubMed ID: 16902988
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel role of IL-13Rα2 in human Glioblastoma multiforme: interleukin-13 mediates signal transduction through AP-1 pathway.
Bhardwaj R; Suzuki A; Leland P; Joshi BH; Puri RK
J Transl Med; 2018 Dec; 16(1):369. PubMed ID: 30572904
[TBL] [Abstract][Full Text] [Related]
13. An interleukin 13 receptor α 2-specific peptide homes to human Glioblastoma multiforme xenografts.
Pandya H; Gibo DM; Garg S; Kridel S; Debinski W
Neuro Oncol; 2012 Jan; 14(1):6-18. PubMed ID: 21946118
[TBL] [Abstract][Full Text] [Related]
14. Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-targeted cytotoxin composed of IL-13 antagonist and Pseudomonas exotoxin.
Kioi M; Kawakami K; Puri RK
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6231-8. PubMed ID: 15448012
[TBL] [Abstract][Full Text] [Related]
15. Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model.
Kawakami K; Kawakami M; Kioi M; Husain SR; Puri RK
J Neurosurg; 2004 Dec; 101(6):1004-11. PubMed ID: 15597761
[TBL] [Abstract][Full Text] [Related]
16. Nitric oxide accelerates interleukin-13 cytotoxin-mediated regression in head and neck cancer animal model.
Kawakami K; Kawakami M; Puri RK
Clin Cancer Res; 2004 Aug; 10(15):5264-70. PubMed ID: 15297430
[TBL] [Abstract][Full Text] [Related]
17. In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures.
Joshi BH; Leland P; Asher A; Prayson RA; Varricchio F; Puri RK
Cancer Res; 2001 Nov; 61(22):8058-61. PubMed ID: 11719427
[TBL] [Abstract][Full Text] [Related]
18. Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice.
Li C; Hall WA; Jin N; Todhunter DA; Panoskaltsis-Mortari A; Vallera DA
Protein Eng; 2002 May; 15(5):419-27. PubMed ID: 12034862
[TBL] [Abstract][Full Text] [Related]
19. New agents for targeting of IL-13RA2 expressed in primary human and canine brain tumors.
Debinski W; Dickinson P; Rossmeisl JH; Robertson J; Gibo DM
PLoS One; 2013; 8(10):e77719. PubMed ID: 24147065
[TBL] [Abstract][Full Text] [Related]
20. Intratumor administration of interleukin 13 receptor-targeted cytotoxin induces apoptotic cell death in human malignant glioma tumor xenografts.
Kawakami M; Kawakami K; Puri RK
Mol Cancer Ther; 2002 Oct; 1(12):999-1007. PubMed ID: 12481422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]